Heidelberg Pharma Announces Conclusion of License Agreement with Partner Takeda To Develop an Antibody Targeted Amanitin Conjugate

LADENBURG, Germany I September 09, 2022 I Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH and Takeda signed a license agreement granting Takeda an exclusive license to commercially develop an Antibody Targeted Amanitin Conjugate directed to a previously selected target molecule.

Takeda obtained access to Heidelberg Pharma's proprietary Amanitin toxin-linker platform technology under an exclusive multi-target research agreement effective as of June 2017. Takeda provided different antibodies to Heidelberg Pharma to generate new ATACs®. ATACs® are ADCs (Antibody Drug Conjugates) based on Heidelberg Pharma's ATAC® technology.

The license agreement was concluded following Takeda’s exercise of its option to exclusively license the worldwide development and commercialization rights for using the ATAC® technology with an antibody directed to a defined target and the resulting product candidates. Heidelberg Pharma receives an undisclosed milestone payment in return and is eligible to receive potential future clinical development, regulatory and sales-related milestone payments.

Information and Explanation of the Issuer to this announcement:

About Heidelberg Pharma

Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary ATAC® technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. The proprietary technology platform is being applied to develop the Company’s own therapeutic ATACs® as well as in third-party collaborations. The lead candidate HDP-101 is a BCMA ATAC in clinical development for multiple myeloma. HDP-102, a CD37 ATAC for Non-Hodgkin lymphoma and HDP-103, a PSMA ATAC for metastatic castration-resistant prostate cancer, are in preclinical testing.

Heidelberg Pharma AG is based in Ladenburg, Germany, and is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol HPHA. More information is available at http://www.heidelberg-pharma.com/.

SOURCE: Heidelberg Pharma

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top